Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04505839 · ClinicalTrials.gov registry record · Phase 1
First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors
A Phase 1 study, sponsored by ST Pharm Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT04505839 is a Phase 1 study that has completed, run by ST Pharm Co.. The registered enrollment target is 32 participants.
The verdict
NCT04505839, a Phase 1 study, has completed, sponsored by ST Pharm Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics (PK) and to determine the maximum tolerated dose (MTD) of STP1002 in patients with advanced-stage solid tumors.
Interventions
- DRUG STP1002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2020-07-30 |
| Est. Completion | 2023-03-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04505839
The ClinicalTrials.gov registry entry for NCT04505839 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ST Pharm Co., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which STP1002 is the first listed.
NCT04505839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04505839 about?
NCT04505839 is a clinical study titled "First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors". This is an open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics (PK) and to determine the maximum tolerated dose (MTD) of STP1002 in patients with advanced-stage solid tumors.
What is the current status of trial NCT04505839?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2020-07-30. Estimated completion is 2023-03-07.
What interventions are being tested in trial NCT04505839?
The interventions under investigation include: STP1002 (DRUG).
Who is sponsoring clinical trial NCT04505839?
This trial is sponsored by ST Pharm Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.